Patient-Derived Xenografts: A Powerful Tool for Breast Cancer Research and Beyond

Life Sciences, Drug Discovery & Development, Preclinical,
  • Wednesday, May 13, 2020

Less than 10% of investigational anti-cancer drugs successfully achieve approval for clinical use by the FDA. This is not necessarily due to the lack of activity of the compound, but is instead due to a failure to identify patients whose tumors are most likely to respond. Recent research has focused on developing new models that better recapitulate what can be seen in the clinic. One group of such models is the patient-derived xenografts (PDXs).

PDXs are established by directly implanting tumor tissue into an immunocompromised host, most commonly mice, without intermittent passaging of the cells in culture. Increasing evidence indicated that these PDXs not only faithfully conserve biological features of the parental malignancies but also show sensitivity/resistance to the same therapeutic agents. Well-characterized PDX models, with accompanying genome sequencing and gene expression data, can help researchers elucidate mechanisms of action of their lead compound. The molecular/mutational signature present in sensitive versus resistant tumors can further be used to generate improved inclusion/exclusion criteria in future clinical trials.

Envigo offers access to over 100 highly-characterized breast cancer PDX models representing all major subtypes through its licensed WHIM (Washington University Human in Mouse) collection from Washington University. This collection of breast cancer tumors offer investigators a powerful tool to test novel drugs in a model where the clinical history of the patient and the mutational landscape of both the parental and PDX tumor is known. The newest addition to this collection includes PDXs established from ER+, pRb+ tumors displaying resistance to the CDK4/6 inhibitor palbociclib, providing an exclusive opportunity to investigate what compounds or combinations might be efficacious in patients with tumors displaying this resistant phenotype.

In this webinar, our featured speaker will discuss the following:

  • What constitutes a patient-derived xenograft and how they are established
  • Why PDX models are more translatable than cell-line-derived models
  • How well-characterized PDX models can help drive drug discovery and clinical success

Speaker

http://E.%20Viktoria%20Hyddmark,,%20Envigo

E. Viktoria Hyddmark, Senior Scientist, Envigo

E. Viktoria Hyddmark received her PhD in Medical Sciences from the University of Florida in 2016 where she trained under the mentorship of Drs. Ghivizzani and Gibbs. She then did a postdoc in the lab of Dr. Thomas Tedder in the department of pediatric allergy and immunology at Duke University. She joined the in vivo business unit at Horizon Discovery, which was subsequently acquired by Envigo, in 2019 as a Senior Scientist.

Message Presenter

Who Should Attend?

This webinar will appeal to individuals with the following or other related job titles:

  • Researcher
  • Principal Investigator
  • Scientist
  • Study Director
  • Head of Research
  • Veterinarian
  • Facility Manager
  • Operations Manager
  • Procurement/Outsourcing

Relevant areas:

  • In vivo research
  • PK/PD research
  • Cancer research
  • Oncology
  • Immuno-oncology

What You Will Learn

  • What constitutes a patient-derived xenograft and how they are established
  • Why PDX models are more translatable than cell-line-derived models
  • How well-characterized PDX models can help drive drug discovery and clinical success

 

Xtalks Partner

Envigo

Envigo provides the broadest range of research models and related services to the pharmaceutical and biotechnology industries, government, academia, and other life science organizations. As the largest organization that is solely dedicated to providing research models and related products and services, we are committed to helping researchers realize the full potential of their critical R&D projects as we fulfill our mission to work together to build a healthier and safer world. Read more at envigo.com.

You Must Login To Register for this Free Webinar

Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.

Create Account